Publications

Researched and Curated by Clinical and Scientific Experts.

Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.

Not all reports are available for public preview. For more information, please contact us.

Lisocabtagene Maraleucel for Large B-Cell Lymphoma

Lisocabtagene maraleucel (liso-cel) is an investigational, autologous chimeric antigen receptor (CAR) T-cell therapy, a novel type of immunotherapy in which a patient’s own immune cells are genetically re-programmed to target and attack cancer cells. It is proposed to treat adults with relapsed or refractory large B-cell lymphoma after at least 2 prior therapies.

Voclosporin for Lupus Nephritis

Voclosporin is an oral, investigational calcineurin inhibitor (CNI) that is similar in structure to cyclosporine. It is proposed as an addition to standard induction therapy for the treatment of active lupus nephritis in adult patients.

Remestemcel-L for Acute Graft-Versus-Host Disease

Remestemcel-L is an allogeneic liquid cell suspension of ex-vivo cultured adult human mesenchymal stem cells derived from healthy donor bone marrow proposed for the treatment of pediatric patients with acute graft-versus-host-disease (aGVHD) refractory to standard first-line steroid therapy.